Similar articles for PMID: 24355130

Year	Number of Results
2001	1
2005	1
2006	2
2007	2
2008	5
2009	7
2010	6
2011	3
2012	8
2013	6
2014	6
2015	3
2016	3
2017	1
2018	2
2019	3
2020	1
2021	2
2022	1
2024	0

1

Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer.

Sridhar J, Sfondouris ME, Bratton MR, Nguyen TL, Townley I, Klein Stevens CL, Jones FE. Sridhar J, et al. Bioorg Med Chem Lett. 2014 Jan 1;24(1):126-31. doi: 10.1016/j.bmcl.2013.11.064. Epub 2013 Dec 3. Bioorg Med Chem Lett. 2014. PMID: 24355130

2

Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.

Vazquez-Martin A, Colomer R, Brunet J, Menendez JA. Vazquez-Martin A, et al. Int J Oncol. 2007 Oct;31(4):769-76. Int J Oncol. 2007. PMID: 17786307

3

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F. Valabrega G, et al. Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9. Breast Cancer Res Treat. 2011. PMID: 21153051

4

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G. Dua R, et al. Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27. Breast Cancer Res Treat. 2010. PMID: 19859802

5

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Tseng PH, et al. Mol Pharmacol. 2006 Nov;70(5):1534-41. doi: 10.1124/mol.106.023911. Epub 2006 Aug 3. Mol Pharmacol. 2006. PMID: 16887935

6

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. Osipo C, et al. Oncogene. 2008 Aug 28;27(37):5019-32. doi: 10.1038/onc.2008.149. Epub 2008 May 12. Oncogene. 2008. PMID: 18469855

7

Correlation of phosphorylated HER2 with clinicopathological characteristics and efficacy of trastuzumab treatment for breast cancer.

Ramić S, Asić K, Balja MP, Paić F, Benković V, Knežević F. Ramić S, et al. Anticancer Res. 2013 Jun;33(6):2509-15. Anticancer Res. 2013. PMID: 23749902

8

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S. Cameron DA, et al. Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594499 Review.

9

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM. Nahta R, et al. Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Clin Breast Cancer. 2010. PMID: 21115425 Review.

10

Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab.

Goldblatt EM, Erickson PA, Gentry ER, Gryaznov SM, Herbert BS. Goldblatt EM, et al. Breast Cancer Res Treat. 2009 Nov;118(1):21-32. doi: 10.1007/s10549-008-0201-4. Epub 2008 Oct 14. Breast Cancer Res Treat. 2009. PMID: 18853252

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

50 results

Results by year